How Deghor 120mg Injection works?

Deghor Injection blocks gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland that lowers down testosterone production in the body. As a result, inhibits testosterone driven prostrate cancer.

Can we Self Administer the Deghor 120mg Injection?

No, it is not advised to self administer the Deghor Injection until and unless you yourself are not a doctor or professional, experienced health care personnel.

Can I take Deghor 120mg Injection during Pregnancy?

No, Deghor Injection is not recommended for administration during pregnancy. It causes harm to developing baby in the womb.

Are there any serious side effects of Deghor 120mg Injection?

Yes, there are serious side effects of Deghor Injection such as severe allergic reactions, injection site reactions, heart rhythm changes etc.

Deal of the Day — limited-time pharmacy picks!Deal of the Day — today's spotlight pharmacy prices, refreshed daily.

Deghor 120mg Injection

Name: Deghor 120mg Injection
Brand: Deghor
Price: 14000 INR
Availability: InStock
Rating: 4.29 (7 reviews)

Rx Required

Salt Composition: Degarelix

Expiry Date: 01/2028

Buy at $247.06

$247.06

Inclusive of all taxes

▼

1 Injection

About The Product

Prostate Cancer

Description

Deghor 120mg Injection is a doctor prescribed Hormone therapy based anticancer injection that is used to treat advanced prostate cancer in adult men.

Deghor 120mg Injection contains 120mg of degarelix as its active salt, a synthetic GnRH receptor antagonist that blocks the gonadotropin-releasing hormone (GnRH) receptors to reduce male hormone production that drive the cancer.

Indication

Prostate Cancer

Faqs

Deghor 120mg Injection is used to treat advanced prostate cancer in adult men.

References

• Persson, B. E., Kold Olesen, T., & Jensen, J.

K. (2009).

Degarelix: a new approach for the treatment of prostate cancer. Neuroendocrinology, 90(3), 235-244. • Carter, N.

J., & Keam, S. J.

(2014). Degarelix: a review of its use in patients with prostate cancer.

Drugs, 74(6), 699-712. • Shore, N. D.

(2013). Experience with degarelix in the treatment of prostate cancer.

Therapeutic advances in urology, 5(1), 11-24. • Klotz, L., Boccon‐Gibod, L., Shore, N. D., Andreou, C., Persson, B.

E., Cantor, P., ... & Schröder, F. H.

(2008). The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer.

BJU international, 102(11), 1531-1538.

Last updated: 5 Aug 2026 | 04:33 PM (IST)

Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only

Not a substitute for professional medical advice

Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.

Read full medical disclaimer in Terms & Conditions